Publications by authors named "Mamoudou N Conde"
Background: In 2014-2015, we assessed favipiravir tolerance and efficacy in patients with Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been used before for this indication and that high concentrations of the drugs were needed to achieve antiviral efficacy against EBOV, a pharmacokinetic model had been used to propose relevant dosing regimen. Here we report the favipiravir plasma concentrations that were achieved in participants in the JIKI trial and put them in perspective with the model-based targeted concentrations.
View Article and Find Full Text PDFCorrection: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.
Daouda Sissoko Cedric Laouenan Elin Folkesson Abdoul-Bing M'Lebing Abdoul-Habib Beavogui Mamoudou N Conde Conde Sekou
PLoS Med
April 2016
[This corrects the article DOI: 10.1371/journal.pmed.
View Article and Find Full Text PDFArticle Synopsis
- Ebola virus disease (EVD) is highly fatal, and during the 2014 outbreak, the WHO identified favipiravir as a potential treatment, but ethical concerns prevented randomized trials.
- Instead, a multicenter non-randomized trial was conducted where all patients received favipiravir to assess its feasibility, safety, and effectiveness in treating EVD.
- Participants were selected based on specific criteria and received a set dosage of favipiravir, with the goal of gathering preliminary data to inform future research rather than establish definitive treatment guidelines.